Clinical trial Recruiting at 2 sites Interventional Ages 18 and up Women only

Continuous glucose monitoring versus finger‑stick checks in pregnancy with type 2 diabetes

Official title: Maternal Continuous Glucose Monitoring Surveillance Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

Run by Thomas Jefferson University · NCT07184775 · Data updated 2026-11-12

This trial tests whether wearing a continuous glucose monitor helps pregnant people with type 2 diabetes keep up with blood sugar checks more than traditional finger‑stick testing.

More Pregnancy trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment70 (estimated)
SponsorThomas Jefferson University
Academic / other
Locations2 sites (Sewell, New Jersey and 1 other locations)
StatusRecruiting
StartedOctober 1, 2025
Main results expectedMarch 1, 2026
Study endsMarch 1, 2026
Registry record updatedOctober 14, 2025
Trial IDNCT07184775 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are pregnant people with singleton pregnancies and pregestational type 2 diabetes who start prenatal care before 20 weeks and can wear a continuous glucose monitor.

Probably not a fit

People with type 1 diabetes, those allergic to insulin, or those unable or unwilling to wear a CGM are unlikely to benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial assigns pregnant people with pregestational type 2 diabetes to either standard finger‑stick glucose monitoring or to wearing a continuous glucose monitor during pregnancy. The main goal is to compare adherence to glucose monitoring between the two methods, with secondary analyses of maternal glycemic control and neonatal outcomes. Eligible participants are those with singleton pregnancies without fetal anomalies who begin prenatal care before 20 weeks; people with type 1 diabetes, insulin allergy, or inability to wear a CGM are excluded. Medication adjustments follow routine clinical care based on the glucose data collected from the assigned monitoring method.

Why it matters

Potential benefit: If successful, CGMs could make it easier to track blood sugar during pregnancy and lead to better glucose control and healthier newborn outcomes.

How similar studies have gone: Previous studies in pregnancy and other diabetes populations have shown CGMs increase monitoring adherence and improve glycemic control, but randomized evidence specifically in pregestational T2DM pregnancies is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* singleton pregnancies
* fetuses without anomalies
* diagnosis of Type 2 diabetes
* initiation of prenatal care at \<20 weeks gestation

Exclusion Criteria:

* diagnosis of Type 1 diabetes
* allergy to insulin
* inability to wear a continuous glucose monitor

Where it's running

  • Jefferson Health New Jersey
    Sewell, New Jersey, United States
    Recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.